Recent Publications:

1. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, Kwint TL, Chan T, Bastien N, Charest H, and Li Y.(2009). Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect  Dis. 199: 168-179.
2. Yan KX, Tan WJ, Wang HJ, Wang Y, Zhang XM, Li Y, and Ruan L. (2009). SARS-CoV spike protein expressed in vaccinia virus TianTan strain: secreted SQ protein induced robust neutralization antibody in mice. Viral Immunology.  22: 57-65.
3. Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X, Kobasa D, and Kobinger G. (2009). Evaulation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine. 27: 3083-3089.
4. Bastien N, Burton L, Bontovics E, Winter AL, McNab B,Tipples G, and Li Y. (2009). Parotitis in a child infected with triple reassortant influenza A virus in Canada in 2007.  J. Clin. Microbiol.47: 1896-1898.
5. Luo L, Sabara M, and Li Y. (2009). Analysis of antigenic cross-reactivity between subgroup C avian penumovirus (APV) and human metapneumovirus (hMPV) by using recombinant fusion (F) proteins. Transboun Emerg Dis. 56: 303-310.
6. Culter J, Schleihaul E, Hatchette T, Billard B, Waston-Creed G, Davidson R, Li Y, and Sarwal S. (2009). The first case of human to human transmission of A/H1N1 human swine influenza in Canada. CMAJ. 181: 159-163.
7. Zhao L, Qian Y, Zhu R, Deng J, Wang F, Dong H, Sun Y, and Li Y. (2009). Human bocavirus infections are common in Beijing population indicated by sero-antibody prevalence analysis. Chin Med J. 122 (11): 1289-1292.
8. Hatchette TF, Bastien N, Berry J, Booth TF, Chernesky M, Couillard M, Drews S, Ebsworth A, Fearon M, Fonseca K, Fox J, Gagnon JN, Guercio S, Horsman G, Jorowski C, Kuschak T, Li Y, Majury A, Petric M, Ratnam S, Smieja M, Van Caeseele P; Pandemic Influenza Laboratory Preparedness Network (2009). The limitations of point of care testing for pandemic influenza: what clinicians and public health professionals need to know. Can J Public Health. 100: 204-207.
9. Zhao L, Qian Y, Ding Y, Zhu R, Deng J, Wang F, Sun Y, and Li Y. (2009). The expression of the capsid protein VP2 from human bocavirus identified in Beijing and the formation of virus-like particles (VLPs) in insect cells. Chin J. Virol. 25 (5): 332-338.
10. LeBlanc J, Li Y, Bastien N, Forward, K, Davidson R, and Hatchette T. (2009). Switching gears for a pandemic: validation of a duplex RT-PCR for simultaneous detection and confirmation of pandemic influenza A (H1N1).J. Clin. Microbiol.3805-3813.
11. Papenburg J, Karatzios C, Li Y, Bastien N, Semret M, and Moore D. (2009). A near-fatal infection with oseltamivir-resistant influenza A in a previously healthyu child: case report. Can J Infect Dis Med Microbiol. 20: e173-e176.
12. Luo L, Hose K, Liu L, Sabara M, and Li Y. (2010). Characterization of the biosynthesis and cell surface expression of avian metapneumovirus attachment glycoprotein. Virus Research. 189-194.
13. Weingartl HM, Berhane Y, Neufeld JKehler H, Emburr-Hyatt C, Hooper-McGerrv K, Kasloff S, Dalman D, Bystrom J, Alexandersen S, Li Y, and Pasick J. (2010). Genetic and pathobiological characterization of pandemic H1N1 2009 viruses from a naturally infected swine herd. J. Virol. 84: 2245-2256.
14. Bastien N, Antonishyn NA, Brandt K, Wong CE, Chokani K, Vegh N, Horsman GB, Tyler S, Graham M, Plummer F, Levett PN, and Li Y (2010). Human infection with a triple-reassortant swine influenza A (H1N1) containing HA and NA genes of seasonal influenza. J Infect Dis. 201: 1178-1182.
15. De Serres G, Rouleau I, Hamelin M, Quach C, Skowronski DM, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault AM,  Couillard M, Charest H, Boivin G (2010). Contagious period for pandemic (H1N1) 2009.Emerg Infect Dis.16: 783-788.
16. Skowronski DM, De Serres G, Crowcroft N, Janjua NZ, , Boulianne N, Hottes T, Rosella LC, Dickinson J, Gilca R, Sethi P, Ouhoummane N, Willison DJ, Rouleau I, Petric M, Fonseca K, Drews SJ, Rebbapragada A, Charest H, Kwindt TL, Hamelin ME, Boivin G, Gardy JL, Li Y, Kwindt TL, Patrick DM, Brunham RC; Canadian SAVOIR Team (2010). Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Medicine. Apr 6;7(4): e1000258.
17. Keynan Y, Card CM, Ball BT, Li Y, Plummer FA, and Fowke KR. (2010). Cellular immune responses to recurring influenza strain have limited boosting ability and limited cross reactivity to other strains. Clin. Microbiol. Infect.  16: 1179-1186.
18. Zahariadis G, Joffe AR, Tablot J, deVilliers A, Campbell P, Pabbaraju K, Wong S, Bastien N, Li Y, Mitchell R, Pang X, Yanow S, Chui L, Predt G, Willans D, Lee B, Preiksaitis J, and Fonsca K. (2010). Identification and epidemiology of severe respiratory disease due to novel swine-origin influenza A (H1N1) virus infection in Alberta. Can J Infect Dis Med Microbiol.. 21(4): e151-e157.
19. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI and Gubareva LV (2010). Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2: 2269-2289.
20. Douville DN, Lissitsyn Y, Hirschfeld AF, Becker A, Kozyrskyj A, Liem J, Bastien N, Li Y, Victor RE, Sekhon M, Turvey SE, and HayGlass K (2010). TLR4 Asp299Gly and Thr399Ile Polymorphisms: No Impact on Human Immune Responsiveness to LPS or Respiratory Syncytial Virus. PLoS One. Aug 10;5(8). pii; e12087.
21. Kropp RY, Bogaert LE, Barber R, Tremblay FW, Ennis R, Tepper M, Pless R, Bastien N, Li Y, Beaudoin C, Anderson J, Pelletier L, and Rodin R. (2010). Pandemic (H1N1) 2009 outbreak at a Canadian forces cadet camp.Emerg Infect Dis.16(12): 1986-1989.
22. Michaiski CJ, Li Y, and Kang CY. (2010). Induction of cytopathic effects and apoptosis in Spodoptera frugiperda cells by the HIV-1 Env glycoprotein signal peptide. Virus Genes. 41 (3): 341-350.
23. Luo L, Nishi K, MacLeod E, Sabara IM, and Li Y. (2010). Analysis of expression and glycosylation of avian metapneumovirus attachment glycoprotein from recombinant baculovirus. Virus Research.153(2): 244-249.
24. Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Alpuche Aranda C, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, and Feldmann H. (2011). Pandemic swine-origin H1N1 influenza A isolates show heterogeneous virulence in macaques. J. Virol. 85(3): 1214-1223.
25. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson J, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay J, Bastien N, Li Y, and Petric M. (2011). Effectiveness of AS03-adjuvanted pandemic H1N1 vaccine: estimates from the sentinel system in Canada, fall 2009. BMJ. 342: c7297.
26. Sheu TG, Fry AM, Garten RJ, Deyde VM, Peebless P, Li Y, Klimov AI, and Gubareva LV. (2011). Dual resistance to oseltamivir and adamantanes among seasonal influenza A (H1N1) viruses: 2008-2010. J Infect  Dis. 203(1): 13-17.
27. Graham M, Liang B ,Van Domselaar G, Bastien N, Tyler S, Beaudoin C, Tyler S, Kaplen B, Landry E, the National Influenza A/H1N1 pdm Genomic Study Team (NIGST) and Li Y. (2011). Nationwide molecular surveillance of pandemic H1N1 influenza A virus genomes: Canada, 2009. PLoS One. 6(1): e16087.
28. Longtin J, Patel SN, Eshagi A, Lombos E, Higgins R, Alexande D, Olsha R, Tran D, Doyle J, Sarabia A, Lee C, Low DE, Li Y, Bovin G, and Gubbay J. (2011). Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.  J. Clin. Virol. 50(3): 257-261.
29. Webster D, Li Y, Bastien N, Garceau R, and. Hatchette T (2011). Oseltamivir-resistant H1N1 pandemic influenza. CMAJ. 183(7): E420-422.
30. Girouard G, Garceau R, Thibault L, Bourque C, Bastien N, and Li Y. (2011). Province-wide adenovirus type 3 outbreak with severe cases in New Brunswick, Canada.Can J Infect Dis Med Microbiol.22(1): e4-e6.
31. Keynan Y, Bodnarchuk, Wayne S, Li Y, and Fowke KR. (2011). Evaluation of influenza-specific humoral response by microbead array analysis.Can J Infect Dis Med Microbiol. 22(1): 25-29.
32. Scheifele DW, Ward B, Dionne M, Vanderkooi O, Langley J, Dobson S, Li Y, Law  B, Halperin SA, for the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators. (2011). Evaluation of adjuvanted pandemic H1N1 ₂₀₀₉ influenza vaccine after one or two doses in young children. Pediatr Infect Dis J. 30(5): 402-407.
33. Coleman BL, Boggild AK, Drews S, Li Y, Low DE, and McGeer AJ. (2011). Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season. Influenza other Respi Viruses. In press.
34. Eshaghi A, Patel S, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, Li Y, Bastien N, Alexander DC, Low DE, and Gubbay JB. (2011). Multidrug-Resistant Pandemic Influenza A (H1N1) Infection in an Immunocompetent Ambulatory Child with no Prior Antiviral Exposure.Emerg Infect Dis17(8): 1472-1474.
35. Rubinstein E, Predy G, Sauvé L, Hammond G, Aoki F, Sikora C, Li Y, Law B, Halperin S, and Scheifele D. (2011). The responses of aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ. 183(13):E1033-1037.
36. Bastien N, Gubbay J, Richardson D, Sleeman K, Gubareva L, and Li Y. (2011).  Detection of of an influenza B strain with reduced susceptibility to neuraminidase inhibitor drugs.J. Clin. Microbiol. 49(11):4020-4021.
37. Coleman BL, Kuster SP, Gubbay J, Scheifele D, Li Y, Low D, Crowcroft N, Mazzulli T, Shi L, Halperin S, Law B, and McGeer A, for the Working Adults Influenza Cohort Study Group. (2011). Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 31(4):591-597.
38. Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft N, Taylor M, Winter AL,Hottes TS, Fonseca K, Charest H, Drews SJ, Sabaiduc S, Bastien N, Li Y, Gardy JL, and Petric M.(2012). Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system: Cross protection against major and minor variants. J Infect Dis. 205(12):1858-68. 
39. Meunier I, Embury-Hyatt C, Stebner S, Gray M, Bastien N, Li Y, Plummer F, Kobinger GP, and von Messling V (2012).Virulence differences of closely related pandemic 2009 H1N1 isolatescorrelate with increased inflammatory responses in ferrets. Virology. 422(1):125-131.
40. Patel A, Gray M, Li Y, Kobasa D, Yao X, and Kobinger G (2012). Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.  Vaccine. 30(3):626-636.  
41. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, Zhou A, Li J, Cao WC, Huang Z, Li Y, and Lu S (2011). Polyvalent DNA Vaccines Expressing HA Antigens of H5N1 Influenza Viruses with an Optimized Leader Sequence Elicit Cross-Protective Antibody Responses. PLoS One.6(12):e28757. 
42. Langley JM, Scheifele D, Quach C, Vanderkoi O, Ward B, McNeil S, Dobson S, Kellner J, Kuhn S, Kollman T, MacKinnon-CameronD, Smith B, Li Y, and Halperin SA (2012). Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12 to 59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine. 30(23):3389-3394.
43. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Gardy JL, Crowcroft NS, Fradet MD,  Bastien N, Li Y, Krajden M, Sabaiduc S, and Petric M (2012). A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-11 season. Clin Infect Dis. 55(3):332-342.
44. Cooper, C., Klein, M., Walmsley, S., Haase, D., MacKinnon-Cameron, D., Marty, K., Li, Y., Smith, B., Halperin, S, Law, B, Scheifele, D, PHAC CIHR Influenza Research Network. (2012). High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1 2009 and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials. 13(1):23-32.
45. Higgins RR, Beniprashad M, Chong-KingE, Li Y, Bastien N, Low DE, and Gubbay JB (2012). Recovery of Influenza B Virus, with H273Y Point Mutation in the Neuraminidase Active Site from a Human Patient. J.Clin Microbiol.50(7):2500-2502.
46. Scheifele DW, Ward B, Dionne M, Vanderkooi O, Loeb M, Colman B, and Li Y. (2012).  Compatibility of ASO3-adjuvanted A/H1N1/2009 influenza vaccine in adults: results of a randomized, controlled trial. Vaccine. 30(32):4728-4732.